Drug intelligence / Profile preview

recombinant human lactoferrin + lysozyme

Development stage: Unknown
Lead developer: Wuhan Healthgen Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

Recombinant Human Lactoferrin and Lysozyme Oral Solution (HY1002) is a biologic combination therapy developed by Wuhan Healthgen Biotechnology for the treatment of rotavirus-induced infectious diarrhea in children. It consists of two recombinant human proteins—lactoferrin and lysozyme—produced using a plant-based expression system (OryzHiExp). Lactoferrin provides broad-spectrum antimicrobial and antiviral activity while modulating the immune response and protecting the intestinal mucosa. Lysozyme acts by hydrolyzing bacterial cell walls and exhibits synergistic antiviral effects. The drug is currently in Phase II clinical development in China.

Other names: Recombinant Human Lactoferrin and Lysozyme Oral Solution

Targets

PGN (Peptidoglycan)ITLN1 (Intelectin-1)Rotavirus particles / virus-host attachment interface

Beyond the preview

Go deeper on recombinant human lactoferrin + lysozyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human lactoferrin + lysozyme.

Explore the full profile